|
|
|
| Recent advances in the study of glucagon like peptide -2 |
| MA Li′na BI Huimin GAO Ling |
| Department of Endocrinology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan 430060, China |
|
|
|
|
Abstract Glucagon like peptide-2 (GLP-2) is a recently discovered gastrointestinal specific growth factor, with a variety of intestinal regulatory function, including: promoting growth, nutrient digestion and absorption of the intestinal mucosa, increasing intestinal blood flow, improving intestinal barrier function, and promoting the repair of intestinal mucosa damage and healing. In view of the above features, GLP-2 has clinical value in many intestinal diseases such as short bowel syndrome and inflammatory bowel disease. GLP-2 plays a biological role by acting on glucagon like peptide-2 receptors (GLP-2R). Recent experiment data suggest that GLP-2 has a beneficial effect on glucose metabolism, especially for conditions related to increased energy intake. In this paper, the generation, secretion, metabolism and physiological functions of GLP-2 are summarized, and the latest research progress of GLP-2 physiological function is discussed.
|
|
|
|
|
|
[1] Yazbeck R，Howarth GS，Abbott CA. Growth factor based therapies and intestinal disease：is glucagon-like peptide-2 the new way forward [J]. Cytokine Growth Factor Rev，2009， 20（2）：75-84.
[2] Hansen L，Hare KJ，Hartmann B，et al. Metabolism of glucagon-like peptide-2 in pigs：role of dipeptidyl peptidase Ⅳ [J]. Regul Peptides，2007，138（2-3）：126-132.
[3] Dash S，Xiao C，Morgantini C，et al. Glucagon-like peptide-2 regulates release of chylomicrons from the intestine [J]. Gastroenterology，2014，147（6）：1275.e4-1284.e4.
[4] Guan X，Karpen HE，Stephens J，et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow [J]. Gastroenterology，2006，130（1）：150-154.
[5] Drucker DJ，Yusta B. Physiology and Pharmacology of the enteroendocrine hormone glucagon-like peptide-2 [J]. Annu Rev Physiol，2014，76（76）：561-583.
[6] Schmidt PT，Hartmann B，Bregenholt S，et al. Deficiency of the intestinal growth factor，glucagon-like peptide 2，in the colon of SCID mice with inflammatory bowel disease induced by transplantation of CD4+ T cells [J]. Scand J Gastroenterol，2000，35（5）：522-527.
[7] Meier JJ，Nauck MA，Pott A，et al. Glucagon-like peptide 2 stimulates glucagon secretion，enhances lipid absorption，and inhibits gastric acid secretion in humans [J]. Gastroenterology，2006，130（1）：44-54.
[8] Baldassano S，Bellanca AL，Serio R，et al. Food intake in lean and obese mice after peripheral administration of glu?鄄cagon-like peptide 2 [J]. J Endocrinol，2012，213（3）：277-284.
[9] Guan X，Shi X，Li X，et al. GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility [J]. Am J Physiol Endocrinol Metab，2012，303（7）：E853-E864.
[10] Shi X，Zhou F，Li X，et al. Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons [J]. Cell Metab，2013，18（1）：86-98.
[11] Breen DM，Rasmussen BA，C?觟té CD，et al. Nutrient-sensing mechanisms in the gut as therapeutic targets for diabetes [J]. Diabetes，2013，62（9）：3005-3013.
[12] Guan X. The CNS glucagon-like peptide-2 receptor in the control of energy balance and glucose homeostasis [J]. Am J Physiol Regul Integr Comp Physiol，2014，307（6）：R585-596.
[13] Bahrami J，Longuet C，Baggio LL，et al. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse [J]. Gastroenterology，2010，139（3）：857-868.
[14] Baldassano S，Rappa F，Amato A，et al. GLP-2 as beneficial factor in the glucose homeostasis in mice fed a high fat diet [J]. J Cell Physiol，2015，230（12）：3029-3036.
[15] Baldassano S，Amato A，Caldara GF，et al. Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high-fat diet [J]. Endocrine，2016，54：1-9.
[16] Geloneze B，Lima MM，Pareja JC，et al. Association of insulin resistance and GLP-2 secretion in obesity：a pilot study [J]. Arq Bras Endocrinol Metabol，2013，57（8）：632-635.
[17] Mcardle MA，Finucane OM，Connaughton RM，et al. Mechanisms of obesity-induced inflammation and insulin resistance：insights into the emerging role of nutritional strategies [J]. Front Neuroendocrinol，2013，4（4）：52-57.
[18] Saeidi N，Meoli L，Nestoridi E，et al. Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass [J]. Science，2013，341（6144）：406-410.
[19] Cohen RV，Pinheiro JC，Schiavon CA，et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity [J]. Diabetes Care，2012，35（7）：1420-1428.
[20] Mingrone G，Panunzi S，De G A，et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes [J].N Engl J Med，2012，366（17）：1577-1585.
[21] Shan CY，Yang JH，Kong Y，et al. Alteration of the intestinal barrier and GLP2 secretion in Berberine-treated type 2 diabetic rats [J]. J Endocrinol，2013，218（3）：255-262.
[22] Baldassano S，Amato A，Cappello F，et al. Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet [J]. J Endocrinol，2013，217（1）：11-20.
[23] Hein GJ，Baker C，Hsieh J，et al. GLP-1 and GLP-2 as Yin and Yang of intestinal lipoprotein production：evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states [J]. Diabetes，2013，62（2）：373-381.
[24] Asrih M，Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance [J]. J Endocrinol，2013，218（3）：25-36.
[25] Hameed I，Masoodi SR，Mir SA，et al. Type 2 diabetes mellitus：From a metabolic disorder to aninflammatory condition [J]. World J Diabetes，2015，6（4）：598-612.
[26] Baldassano S，Amato A，Rappa F，et al. Influence of endogenous glucagon-like peptide-2 on lipid disorders in mice fed a high-fat diet [J]. Endocr Res，2016，41（4）：19-25.
[27] Cani PD，Amar J，Iglesias MA，et al. Metabolic endotoxemia initiates obesity and insulin resistance [J]. Diabetes，2007，56（7）：1761-1765. |
|
|
|
